# Research literature on the BPC-157 + TB-500 blend — Wolverine Clinic > Mechanism and preclinical data for the BPC-157 + TB-500 (so-called Wolverine) blend: VEGFR2/Akt/eNOS angiogenesis, LKKTETQ G-actin sequestration, tendon and ligament studies, ophthalmic Phase 3 data on thymosin beta-4. Heavily cited. Two compounds, two mechanisms, eighteen primary citations — and no controlled study of the blend itself. ## What the studies actually show Most of the evidence for this blend is from animal studies — rats and mice with surgically damaged tendons, ligaments, muscles and blood vessels. BPC-157 has a large body of rodent work, almost all from one research group in Zagreb, showing tendon and ligament healing, vascular effects, and gut protection. TB-500 has a somewhat different problem: the most rigorous human data are on full-length thymosin beta-4, the 43-amino-acid parent protein, while TB-500 itself is a 7-amino-acid fragment. The two are related but not identical, and it matters when reading the evidence. On the human side, BPC-157 has three small pilot studies. The blend itself has none. A 2025 systematic review in the HSS Journal examined 36 BPC-157 studies, found only one human study, and reported no clinical safety data. The research page walks through the mechanism and the studies, component by component, with those caveats clearly marked. ## The combination, on paper The Wolverine stack is a co-formulation, not a fusion peptide. BPC-157 and TB-500 are administered together — typically from research vials sold at 5 mg : 5 mg or 5 mg : 10 mg per vial by compounders — but they remain two distinct chemical entities that do not bind to each other. The blend's published rationale, summarized in a 2025 mechanism review, is that the two peptides target non-overlapping pathways: BPC-157 supplies a vascular and connective-tissue mechanism, TB-500 supplies a cytoskeletal and re-epithelialization mechanism, and the additive effect — if any — would be greater than monotherapy [18]. That rationale is plausible. It is also unsupported by any controlled in-vivo combination study. Every published outcome in this section is from a single-agent experiment. ## BPC-157 — vascular and connective-tissue mechanism In isolated rat aortic rings, BPC-157 at 10–100 μg/mL produced concentration-dependent vasodilation and activated the Src–Caveolin-1–endothelial nitric oxide synthase signaling pathway, releasing eNOS from its caveolin-1 anchor to roughly 50% of control values [4]. This is the most direct mechanistic evidence published for BPC-157's reported angiogenic effects. In vitro, BPC-157 at 0.1–0.5 μg/mL up-regulated growth hormone receptor messenger RNA and protein expression in rat Achilles tendon fibroblasts by up to seven-fold by day three, with a downstream increase in fibroblast proliferation and PCNA expression upon subsequent growth-hormone exposure [5]. The mechanism — receptor up-regulation rather than direct growth-factor mimicry — is unusual in the wound-healing literature and has not been independently replicated outside the Sikiric / Chang group. The in-vivo tendon and ligament data are consistent across more than a decade of work from a single laboratory. In rats with surgical Achilles tendon detachment, BPC-157 at 10 μg/kg intraperitoneal once daily produced substantial increases in Achilles functional index, load-to-failure, stiffness, and collagen organization, and partially offset corticosteroid-induced healing impairment [1]. A 90-day study of medial collateral ligament transection reported consistent functional, biomechanical, macroscopic, and histological improvements across intraperitoneal (10 μg/kg or 10 ng/kg), topical (1.0 μg in cream), and oral (0.16 μg/mL in drinking water) routes [2]. In a gastrocnemius crush model (force 0.727 Ns/cm²), 14 days of 10 μg/kg intraperitoneal BPC-157 reduced hematoma and edema, prevented post-injury leg contracture, and normalized creatine kinase, lactate dehydrogenase, AST, and ALT [3]. In the gastrointestinal compartment — the original indication that motivated BPC-157's clinical development — topical 10 μg/kg BPC-157 restored colonic blood supply, activated collateral circulation, and normalized malondialdehyde and nitric oxide markers in rat models of ischemic colitis [6]. Under the development name PL 14736, the compound was advanced through Phase 2 trials for inflammatory bowel disease by Pliva in Croatia; safety was reported but the program was not continued to approval [7]. A 2025 narrative scoping review covered 35 preclinical and one clinical study and concluded that BPC-157 shows broad regenerative activity in animal models but that only three published human pilot studies exist (knee pain, interstitial cystitis, and intravenous safety), with a plasma half-life under 30 minutes and no FDA approval [16]. A 2025 systematic review of off-label orthopaedic-sports-medicine use reached the same general conclusion: clinical use has outpaced the human evidence base [19]. ## TB-500 and thymosin beta-4 — cytoskeletal mechanism TB-500 as sold for research is a synthetic 7-amino-acid fragment (Ac-LKKTETQ-OH) of thymosin beta-4, a 43-amino-acid endogenous peptide. Most of the published thymosin beta-4 literature is on the 43-amino-acid parent rather than on the LKKTETQ fragment specifically — a distinction worth keeping in view when reading any TB-500 dataset. The core mechanism is G-actin sequestration. Thymosin beta-4 binds monomeric (globular) actin so it is not available to polymerize into filaments, regulating the actin cytoskeleton dynamics that drive cell migration. In a 2004 Nature paper, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase, activated the Akt survival pathway, and — after coronary artery ligation in mice — enhanced cardiomyocyte survival and improved cardiac function [9]. A second 2007 Nature paper reported that intraperitoneal thymosin beta-4 (150 μg per dose, repeated) induced adult epicardial progenitor cell mobilization and neovascularization, restoring developmental coronary-vessel programs in adult mice [10]. In a rat embolic stroke model, thymosin beta-4 at 6 mg/kg intraperitoneal (first dose 24 hours after middle-cerebral-artery occlusion, then every three days for four doses) significantly improved functional neurological outcome on adhesive-removal and modified Neurological Severity Score tests, without reducing infarct volume — the effect was attributed to axonal remodeling, oligodendrocyte progenitor proliferation, and increased vessel density at the ischemic boundary [11]. Dermally, thymosin beta-4 has accelerated wound healing in rodent models — including aged and diabetic animals — and Phase 2 trials have reported accelerated repair in pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds [12]. At nanomolar concentrations the peptide stimulates rat vibrissa follicle clonogenic keratinocyte migration and differentiation, increases matrix metalloproteinase-2 secretion, and accelerates hair regrowth in transgenic mice that overexpress it [13]. The most rigorous human data sit in ophthalmology. A randomized, placebo-controlled, double-masked Phase 3 trial of 0.1% RGN-259 (thymosin beta-4) ophthalmic solution dosed five times daily for 4 weeks in neurotrophic keratopathy reported complete corneal healing in 60% (6 of 10) of treated subjects versus 12.5% (1 of 8) of placebo at day 29, with significant continued benefit at day 43 [14]. An earlier Phase 2 trial of 0.1% thymosin beta-4 dosed six times daily for 28 days in nine patients with severe dry eye reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal fluorescein staining at day 56, with a favorable safety profile [15]. ## The combination — what is and isn't known The honest summary: there is no controlled in-vivo combination study of the BPC-157 + TB-500 blend published in the peer-reviewed literature. The combination is plausible on mechanism — BPC-157 supplies VEGFR2/eNOS angiogenesis and gastrointestinal cytoprotection, TB-500 supplies G-actin sequestration and cell migration — and that plausibility is what motivates the stack's use in research and in unregulated practice [18]. What the published reviews emphasize, including a 2025 reply in *Pharmaceuticals* clarifying that BPC-157's angiogenic and nitric-oxide effects are highly context-dependent, is that additive benefit cannot be assumed from non-overlapping mechanisms alone [17][18]. Tissue-repair signaling is bidirectional — protective in injured tissue, but the long-term effects of chronic stimulation of angiogenesis and the actin cytoskeleton are not well characterized. The 2025 BPC-157 musculoskeletal scoping review summarized the state of the human evidence base for BPC-157 as: three published pilot studies. For the BPC-157 + TB-500 blend specifically, that number is zero [16]. ## Active research questions Four open questions matter for any reader of this literature. — **Is the synergy claim falsifiable?** A controlled rat tendon-repair or cardiac-repair study comparing BPC-157 alone, TB-500 alone, and the blend at matched doses would settle it. None has been published. — **Is TB-500 (the fragment) interchangeable with thymosin beta-4 (the parent)?** Most published data are on the 43-amino-acid parent peptide. Whether the LKKTETQ fragment reproduces the full pharmacology of the parent in vivo is not fully established. — **Is the BPC-157 mechanism literature externally valid?** The large majority of the rodent literature comes from a single research group in Zagreb. Independent replication outside that group is comparatively sparse [16][17]. — **What are the long-term safety implications of chronic angiogenic and actin-cytoskeletal stimulation?** Theoretical concerns include pathologic (non-physiologic) angiogenesis, immunogenicity from peptide impurities in compounded products, and unknown effects on tissues with high resident progenitor populations. These have not been characterized in adequately powered human studies. --- Editorial summaries of published research — not clinical guidance, not a vendor, not a prescription service.